{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:03:29Z","timestamp":1791583409354,"version":"4.3.4"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>FDG PET is required for the staging and response evaluation of pediatric Hodgkin lymphoma. This study aimed to evaluate the outcomes of pediatric patients with Hodgkin\u2019s lymphoma based on interim PET CT assessments of early response following second-cycle chemotherapy using the Deauville score (DS). It also determines whether DS\u20133 is providing an adequate or inadequate response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We conducted a retrospective cohort study including 504 pediatric patients with classic Hodgkin lymphoma who were treated with chemotherapy based on the Euro-Net protocol at the Children Cancer Hospital Egypt from March 2019 till the end of October 2022.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Patients with adequate response DS 1\/2 and DS 3 showed nearly the same 3-year event-free survival (EFS) of 91.9% and 91.5%, respectively, compared with those patients with inadequate response DS 4\/5, who showed an EFS of 80.4% (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.001). Patients with a DS 3 at interim PET evaluation were considered negative as DS 1\/2. Patients of DS 3 group who did not receive radiotherapy had a much worse 3-year EFS by the existence of positive B symptoms, an ESR&gt;30, or an advanced stage. Radiation therapy did not improve the 3-year EFS in patients with an inadequate response (DS4\/5) and poor prognostic characteristics. They still need more advanced treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>DS 1\/2 and DS 3 had about the same 3-year EFS, which is better than the 3-year EFS of patients with DS 4\/5. Therefore, we can classify DS 3 as having negative FDG PET CT uptake.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mph.0000000000002943","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T21:25:39Z","timestamp":1724448339000},"page":"e493-e500","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["PET\/CT Response Assessment in Pediatric Hodgkin Lymphoma: Does Deauville Score 3 Reflect Negativity?"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5394-3307","authenticated-orcid":false,"given":"Samah","family":"Semary","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, Children Cancer Hospital Egypt, Cairo"},{"name":"Department of Clinical Oncology, Beni-Suef University, Beni-Suef"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Moussa","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Children Cancer Hospital Egypt, Cairo"},{"name":"Department of Clinical Oncology, Menufiya University, Shebeen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maram","family":"Salama","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Children Cancer Hospital Egypt, Cairo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Fakhry","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Children Cancer Hospital Egypt, Cairo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa","family":"Attia","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Children Cancer Hospital Egypt, Cairo"},{"name":"Department of Pediatric Oncology, National Cancer Institute, Cairo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Mehesen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Children Cancer Hospital Egypt"},{"name":"Department of Nuclear Medicine, National Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Khorshed","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cancer Institute, Cairo University"},{"name":"Department of Pathology, Children Cancer Hospital Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeeha","family":"Elwekeel","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis, National Cancer Institute, Children Cancer Hospital of Egypt, Cairo University"},{"name":"Department of Radiodiagnosis, Children Cancer Hospital of Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Elnashar","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Children Cancer Hospital of Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Sedky","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Children Cancer Hospital Egypt, Cairo"},{"name":"Department of Pediatrics, National Research Centre, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa","family":"Hamoda","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Children Cancer Hospital Egypt, Cairo"},{"name":"Department of Pediatric Oncology, National Cancer Institute, Cairo University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00247-019-04529-8","article-title":"Imaging for diagnosis, staging, and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma","volume":"49","author":"McCarten","year":"2019","journal-title":"Pediatr Radiol"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2013.103218","article-title":"The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale","volume":"99","author":"Gallamini","year":"2014","journal-title":"Haematologica"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2013.53.2838","article-title":"In vivo treatment sensitivity testing with positron emission tomography\/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma","volume":"32","author":"Hutchings","year":"2014","journal-title":"J Clin Oncol"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(21)00470-8","article-title":"Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNetPHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomized controlled trial","volume":"23","author":"Mauz-K\u00f6rholz","year":"2022","journal-title":"Lancet Oncol"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"R6-20250804","author":"Regine"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.clon.2010.08.006","article-title":"Comparison of electronic portal imaging and cone beam computed tomography for position verification in children","volume":"22","author":"Zaghloul","year":"2010","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","article-title":"Concordance between four European centers of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.","volume":"37","author":"Barrington","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the first international workshop on interim-PET-scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F] fluoro-2-deoxy-dglucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/annonc\/mdi272","article-title":"FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma","volume":"16","author":"Mikhaeel","year":"2005","journal-title":"Ann Oncol"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/DDDT.S136988","article-title":"Lugano 2014 Criteria for assessing FDG-PET\/CT in lymphoma: An operational approach for clinical trials","volume":"11","author":"Van Heertum","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.sult.2010.10.001","article-title":"Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy","volume":"31","author":"Kinahan","year":"2010","journal-title":"Semin Ultrasound CT MR"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","article-title":"PET\u2011CT for staging and early response: Results from the response\u2011adapted therapy in advanced Hodgkin lymphoma study","volume":"127","author":"Barrington","year":"2016","journal-title":"Blood"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a randomized, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s43046-023-00189-w","article-title":"Outcome and prognostic factors of pediatric patients with Hodgkin lymphoma: a single-center experience","volume":"35","author":"Ali","year":"2023","journal-title":"J Egypt Natl Canc Inst"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/S2352-3026(21)00349-5","article-title":"Survival by age in pediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children\u2019s oncology group trials.","volume":"9","author":"Kahn","year":"2022","journal-title":"Lancet Haematol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:00:34Z","timestamp":1754337634000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002943","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"2024-03-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}